Genomtec today filed with the Polish Financial Supervision Authority (KNF) a prospectus prepared in connection with the planned transfer of the Company’s listing to the Warsaw Stock Exchange (WSE) main market. The Company’s main motivation for the transfer is to increase its visibility and gain access to a larger group of long-term investors, including foreign ones.
“The transfer of shares to the main market will be another step in the implementation of our long-term strategy. The Company is growing steadily, our key product, Genomtec®ID is in the final stages of development, so we felt it was the right time to change the trading floor. We believe that Genomtec is a valuable company and the transfer of shares will increase our recognition not only among the largest institutional investors in Poland, but will also open the door to foreign investors. We want to build a stable shareholder structure, because MedTech projects are long-term and stability will facilitate our work on commercializing new solutions for patients and the healthcare system” – comments Miron Tokarski, CEO and co-founder of Genomtec.
The Company’s flagship solution Genomtec®ID – a mobile platform for genetic diagnostics – is entering the final stage of development. According to the presented schedule, Genomtec®ID will enter the phase of comparative testing and clinical evaluation of its devices at the turn of the year.
The Company’s next major corporate event will take place on November 8, 2021, when the Company will release and report its Q3 2021 results. During the online conference call, the Company will discuss the next steps in the process of transferring to the main market of the WSE as well as the schedule of commercialisation of Genomtec®ID.
